JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumors
- ER+ Breast Cancer
- Triple Negative Breast Cancer, TNBC
- ARID1A Gene Mutation
- Small Cell Lung Cancer, SCLC
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Last updated on ClinicalTrials.gov
- January 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- Henry Ford Health System · Detroit, MI
Missouri · 1
- Washington University · St Louis, MO
Texas · 1
- Mary Crowley Cancer Research · Dallas, TX
Utah · 1
- University of Utah Huntsman Cancer Institute · Salt Lake City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.